This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 8 Q&As
1 Citations 10 Q&As
Facts about Insulin-like growth factor-binding protein 2.
They alter the interaction of IGFs with their cell surface receptors. .
Human | |
---|---|
Gene Name: | IGFBP2 |
Uniprot: | P18065 |
Entrez: | 3485 |
Belongs to: |
---|
No superfamily |
BP2; IBP2; IBP-2; IGF-binding protein 2; IGFBP2; IGFBP-2; IGF-BP53; insulin-like growth factor binding protein 2 (36kD); insulin-like growth factor binding protein 2, 36kDa; insulin-like growth factor-binding protein 2
Mass (kDA):
34.814 kDA
Human | |
---|---|
Location: | 2q35 |
Sequence: | 2; NC_000002.12 (216632828..216664436) |
Secreted.
Choosing the best method for your research can be a tricky task. Whether you use RT-qPCR to determine mRNA levels, Immunohistochemistry, or ELISA, you need to consider the type of control that is best for your specific experiment. Fortunately, Boster Bio optimization guides can help you make the right decision. Read through the guide to optimize your experiments to get the best results possible.
In cancer studies, the relative abundance of key mRNA biomarkers is used to predict the course of cancer metastasis. Using RT-qPCR to quantify mRNA expression levels in sub-milliliter plasma samples would greatly facilitate basic and clinical research. However, RT-qPCR has several limitations. First, it is limited by the low copy number of cells. Second, it can't distinguish rare transcripts, which result in a decrease in measurement quality. Third, the accuracy of single-molecule qPCR varies widely.
RT-qPCR data represents a snapshot of the total transcript amount in a single cell or tissue. This information is not sufficient to determine the biological significance of variable mRNA levels, as it must also consider the levels of regulatory RNAs and protein activity. The entire protocol takes about 15 h. However, the results can be interpreted from the Cq value. For analyzing multiple samples in one experiment, one can use two-step RT-qPCR.
The first step in RT-qPCR is determining the amount of template mRNA. In this step, RNA is extracted using a PureLink RNA Mini Kit from Thermo Fisher Scientific. Next, the RNA is primed for 5 min at 25 degC. After that, the reverse-transcription reaction is completed for 30 min at 42 degC, after which the reverse-transcriptase is inactivated for 5 min at 85 degrees Celsius. The resulting cDNA is diluted 1:10 in nuclease-free water and stored at -20 degC. RT-qPCR reactions contain 0.4 uM primers and SsoFast EvaGreen Supermix.
A zero-step RT-qPCR method, meanwhile, does not require RNA extraction and separate reverse-transcription steps. The resultant mRNA levels are measured from dilution series samples of LUHMES cells. The VolcanoCell2G 2x RT-qPCR master mix includes forward primers and a hydrolysis probe. Using this procedure will yield the mRNA concentrations.
The ELISA for the IGFBP2 protein is an immunoassay used to measure the protein IGFBP2. This enzyme-linked immunosorbent assay detects the IGFBP2 protein. This marker is associated with BMI. The evolution of this protein and BMI has a strong negative correlation. In fact, the relationship between these two markers is inverse. The researchers have not yet been able to prove causality.
The mouse IGFBP2 marker ELISA measures the amount of the protein in serum, plasma, and cell culture medium. It recognizes both natural and recombinant forms of IGFBP2.
Although it is not completely understood why high levels of the protein can be associated with cancer and CVD risks, it has been found to be a novel target for cancer therapy. Furthermore, IGFBP-2 has anti-apoptotic properties, which makes it a valuable biomarker for lung adenocarcino. But despite these positive results, it is important to understand how this protein is regulated.
The ELISA for the IGFBP2 protein is used to detect the presence of autoantibodies against the TAA IGFBP2. It has recently been used in cancer diagnosis as an immunodiagnostic marker. In a recent study, patients with lung cancer and other benign diseases had higher anti-IGFBP-2 antibodies than normal controls. Since lung cancer patients are often diagnosed at an advanced stage, the presence of this marker can provide a diagnosis for lung cancer.
Although the IGFBP-2 protein has a positive correlation with lung cancer, it is not entirely clear whether it can serve as a marker for a specific disease. There are several potential uses for this marker. For instance, it is used in lung cancer diagnosis, in the detection of lung cancer and substages of the disease. Furthermore, this biomarker has a significant impact on the diagnosis of cancer.
When you need to find the IGFBP2 marker in your samples, the best way to get accurate results is to use a reagent that can detect the protein in the samples. Boster Bio has high affinity primary antibodies that are validated by Western Blotting, Immunohistochemistry, and ELISA. They are produced using recombinant polypeptides or recombinant proteins, and each antibody represents an epitope specific to the antigen.
This antibody can distinguish patients with lung cancer from healthy controls and those with lung benign disease, and it can also be used as a diagnostic tool in the detection of lung cancer. Because it is a biomarker of IGFBP2, it is a useful tool to differentiate lung cancer from other types of lung disease. It can also help doctors distinguish substages of lung cancer by measuring levels of autoantibodies against IGFBP-2.
The CCK-8 is a reagent that can be purchased from Boster Bio. The BIU87 cells were plated at 1x104 per well in a 96-well plate. The cells were exposed to 3 mM cisplatin for varying lengths of time. After cisplatin exposure, 10 ml of the CCK-8 cell counting reagent was added to the samples. Incubation was performed at 37degC for 4 h.
PMID: 2479552 by Binkert C., et al. Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2).
PMID: 1697583 by Zapf J., et al. Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia.
*More publications can be found for each product on its corresponding product page